MESOBLAST LIMITED - Charts / Financials

Market Cap $1.113B Add to my watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

REFRESH

Last update - 15.59pm 15/11/2024 (20 minute delay)

Day
Open	$1.72		Day High	$1.74		Day Low	$1.52
Daily Volume	9716917

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	$1.57	5127		4	$1.57	44837

Directors & Senior Management

Dr. Silviu Itescu	Chief Executive Officer, Executive Director
Mr. William M. Burns	Non-Executive Independent Vice Chairman of the Board
Mr. Andrew Chaponnel	Interim Chief Financial Officer
Ms. Dagmar Rosa-Bjorkeson	Chief Operating Officer
Mr. Peter Howard	General Counsel, Corporate Executive
Dr. Eric A. Rose	Executive Director, Chief Medical Officer
Mr. Justin Horst	Head of Manufacturing
Mr. Michael Schuster	Pharma Partnering
Ms. Geraldine Storton	Head of Regulatory Affairs and Quality Management
Mr. Paul Hughes	Joint Company Secretary
Mrs. Jane Bell	Non-Executive Independent Chairman of the Board
Mr. Philip J. Facchina	Non-Executive Independent Director
Mr. Philip R. Krause	Non-Executive Independent Director
Mr. Joseph R. Swedish	Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last $1.57		Change -0.210(11.8%)		Mkt cap ! $1.113B

Open	High	Low	Value	Volume
$1.72	$1.74	$1.52	$15.63M	9.716M

Buyers (Bids)

No.	Vol.	Price($)
1	5127	$1.57

Sellers (Offers)

Price($)	Vol.	No.
$1.57	44837	4

View Market Depth

No.	Vol.	Price($)
1	2	1.375
1	82	1.370
1	3981	1.365
7	49392	1.360
1	4134	1.355

Price($)	Vol.	No.
1.385	247	1
1.400	4328	1
1.405	12000	2
1.410	18724	1
1.420	12000	2

Last trade - 16.10pm 15/11/2024 (20 minute delay)


Last $1.56		Change -0.210 ( 12.9 %)
Open	High	Low	Volume
$1.71	$1.74	$1.52	1536395
Last updated 15.59pm 15/11/2024 ?

MSB (ASX) Chart